- Report
- March 2024
- 138 Pages
Global
From €3717EUR$3,899USD£3,176GBP
- Report
- February 2024
- 130 Pages
Global
From €5673EUR$5,950USD£4,847GBP
- Report
- January 2024
- 120 Pages
Global
From €5673EUR$5,950USD£4,847GBP
- Report
- January 2024
- 135 Pages
Global
From €5673EUR$5,950USD£4,847GBP
- Report
- July 2023
- 150 Pages
Global
From €5673EUR$5,950USD£4,847GBP
- Report
- May 2024
- 193 Pages
Global
From €4719EUR$4,950USD£4,032GBP
- Report
- May 2024
- 194 Pages
Global
From €5196EUR$5,450USD£4,440GBP
- Report
- May 2024
- 92 Pages
Global
From €5339EUR$5,600USD£4,562GBP
- Report
- November 2023
- 149 Pages
Global
From €2383EUR$2,499USD£2,036GBP
- Report
- October 2023
- 143 Pages
Global
From €2383EUR$2,499USD£2,036GBP
- Report
- February 2024
- 175 Pages
Global
From €4767EUR$5,000USD£4,073GBP
- Report
- February 2024
- 175 Pages
Global
From €4767EUR$5,000USD£4,073GBP
- Report
- February 2024
- 175 Pages
Global
From €4767EUR$5,000USD£4,073GBP
- Report
- February 2024
- 200 Pages
Global
From €4767EUR$5,000USD£4,073GBP
- Report
- November 2023
- 250 Pages
Global
From €4767EUR$5,000USD£4,073GBP
- Report
- October 2023
- 183 Pages
Global
From €4672EUR$4,900USD£3,992GBP
- Report
- August 2023
- 150 Pages
Global
From €4624EUR$4,850USD£3,951GBP
- Report
- February 2024
- 184 Pages
Global
From €4672EUR$4,900USD£3,992GBP
- Report
- October 2023
- 190 Pages
Global
From €4672EUR$4,900USD£3,992GBP
- Report
- October 2023
- 180 Pages
Global
From €4672EUR$4,900USD£3,992GBP
The Antisense Oligonucleotide market is a segment of the biotechnology industry that focuses on the development of drugs that use short strands of nucleic acids to target and inhibit the expression of specific genes. These drugs are used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. Antisense oligonucleotides are designed to bind to a specific mRNA sequence, blocking the translation of the gene into a protein. This technology has the potential to revolutionize the treatment of many diseases, as it can be used to target specific genes without affecting other parts of the body.
The Antisense Oligonucleotide market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. Other companies in the market include Regulus Therapeutics, Dicerna Pharmaceuticals, and Quark Pharmaceuticals. Show Less Read more